PERINDOPRIL ( DrugBank: Perindopril )
4 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
58 | 肥大型心筋症 | 1 |
113 | 筋ジストロフィー | 2 |
167 | マルファン症候群 | 3 |
222 | 一次性ネフローゼ症候群 | 1 |
58. 肥大型心筋症
臨床試験数 : 126 / 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2015-004317-24-IT (EUCTR) | 22/06/2017 | 09/09/2021 | A pilot-study to assess Coronary Flow reserve and post-vasodilation Myocardial Blood Flow , measured by PET with 13N-Ammonia, before and after a six-month long treatment with the ACE-Inhibitor Perindopril, in patients with moderate and high-risk Hypertrophic Cardiomyopathy | A pilot study to assess Coronary Flow Reserve and post-vasodilatatory Myocardial Blood Flow (post-Dipi gMBF), measured by 13N-NH3 PET/CT, before and after a six months-long treatment with the ACE-inhibitor Perindopril, in moderate and high-risk HCM patients”A multicentric, interventional, open label, perspective-design, single-arm, pilot” clinical Study. - CARAPaCe (CoronAry Reserve After Perindopril in hypertophic Cardiomyopathy) | Hypertrophic Cardiomyopathy (primitive) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: PROCAPTAN - 10 MG COMPRESSE RIVESTITE CON FILM 60 COMPRESSE IN CONTENITORE PER COMPRESSE PP Product Name: procaptan INN or Proposed INN: PERINDOPRIL ARGININA Other descriptive name: perindopril arginine Trade Name: PROCAPTAN - 5 MG COMPRESSE RIVESTITE CON FILM 10 COMPRESSE IN CONTENITORE PER COMPRESSE PP Product Name: procaptan INN or Proposed INN: PERINDOPRIL ARGININA Other descriptive name: perindopril arginine | AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 21 | Phase 2 | Italy |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2000032525 | 2020-05-01 | 2020-05-01 | Early intervention for subclinical myocardial prevention of ACEI and beta-blocker in patients with Duchenne muscular dystrophy: a prospective multicenter randomized controlled clinical trial | Early intervention for subclinical myocardial prevention of ACEI and beta-blocker in patients with Duchenne muscular dystrophy: a prospective multicenter randomized controlled clinical trial | Duchenne muscular dystrophy | Group A:Perindopril;Group B:metoprolol;Group C:Perindopril and metoprolol; | West China Second University Hospital, Sichuan University | NULL | Recruiting | 1 | 18 | Male | Group A:106;Group B:106;Group C:106; | Phase 4 | China |
2 | EUCTR2007-005932-10-GB (EUCTR) | 30/03/2009 | 14/04/2009 | A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction - DMD-Heart Protection | A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction - DMD-Heart Protection | Duchenne muscular dystrophy MedDRA version: 9.1;Level: LLT;Classification code 10013801;Term: Duchenne muscular dystrophy | Trade Name: Perindopril 2mg Tablets Product Name: Perindopril Trade Name: Cardicor (Merck brand) Product Name: Bisoprolol | Newcastle upon Tyne Hospitals NHS Foundation Trust | NULL | Not Recruiting | Female: no Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United Kingdom |
167. マルファン症候群
臨床試験数 : 21 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01295047 (ClinicalTrials.gov) | July 2006 | 11/2/2011 | Comparison of Medical Therapies in Marfan Syndrome. | Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial | Marfan Syndrome | Drug: Atenolol;Drug: VERAPAMIL;Drug: Perindopril | Cardiff University | NULL | Completed | 16 Years | 60 Years | Both | 18 | Phase 4 | United Kingdom |
2 | EUCTR2005-000749-13-GB (EUCTR) | 30/07/2005 | 20/06/2005 | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | Marfan Syndrome | Trade Name: Atenolol Product Name: Atenolol Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A Trade Name: Coversyl Product Name: Coversyl Product Code: N/A INN or Proposed INN: N/A Other descriptive name: PERINDOPRIL Trade Name: Verapamil Product Name: Verapamil SR Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A | Cardiff University | NULL | Not Recruiting | Female: yes Male: yes | 60 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom | ||
3 | NCT00485368 (ClinicalTrials.gov) | January 2004 | 11/6/2007 | Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome | The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome. | Marfan Syndrome | Drug: Coversyl (perindopril) | Bayside Health | Baker Heart Research Institute;The Alfred | Completed | 18 Years | 40 Years | Both | 17 | Phase 3 | NULL |
222. 一次性ネフローゼ症候群
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR1900021757 | 2019-03-01 | 2019-03-08 | A randomized controlled trial for hydroxychloroquine sulfate in the treatment of idiopathic membranous nephropathy | The efficacy and safety of hydroxychloroquine sulfate in idiopathic membranous nephropathy: A randomized, controlled, Single-center clinical trial | Idiopathic Membranous Nephropathy | Group 1:Supportive treatment+Perindopril 8 mg/day;Group 2:Supportive treatment+Perindopril 8 mg/day+hydroxychloroquine sulfate (200mg 2/d);Group 3:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml);Group 4:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml)+hydroxychloroquine sulfate (200mg 2/d); | Nephrology Division, First Hospital Affiliated to Army Medical University | NULL | Recruiting | 18 | 60 | Both | Group 1:55;Group 2:55;Group 3:55;Group 4:55; | Phase 4 | China |